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Background
Considerable evidence indicates that, in addition to anti-
allergic effect, several H1-antihistamines also possess anti-
inflammatory properties. The anti-inflammatory activity of
H1 antihistamine treatment in urticaria patients is based
on the capacity of H1-antihistamines to inhibit the release
of chemical mediators from mast cells and basophiles, to
regulate the chemotaxis of neutrophils and eosinophils, to
increase eosinophils apoptosis and to reduce the expres-
sion of the adhesion molecules. Viral hepatic infections
may affect the efficacy of H1 antihistamines probably
interfering with their hepatic metabolism through cyto-
chrome P450 system. We proposed to analyze the effect of
hepatitis C virus (HCV) infection on the therapeutic effi-
cacy of H1 antihistamines in urticaria patients.
Methods
The study included 37 acute and chronic spontaneous
urticaria patients divided into two groups (A,B) depend-
ing on the associated HCV infection. Group A consisted
of 30 urticaria patients without HCV infection and
group B included 7 urticaria patients associating HCV
infection. The experimental analysis targeted the
dynamic of urinary histamine level (spectrofluorimetric
method) depending on the Urticaria Activity Score
(UAS) and C-reactive protein (CRP) level in patients
with urticaria, during the treatment with H1-antihista-
mines. The clinical and paraclinical evaluations were
done at the study entry and at 2 weeks after initiating
the H1-antihistamine treatment.
Results
We obtained much stronger correlations between urinary
histamine level and UAS, respectively CRP, for patients in
group A (r = 0.924, p < 0.05, respectively r = 0.548,
p < 0.05 at study entry and r = 0.511, p < 0.05, respectively
r = 0.286, p < 0.05 after two weeks of H1-anti histamine
treatment) comparing to those in group B (r = 0.836,
p < 0.05, respectively r = 0.491, p < 0.05 at study entry and
r = 0.484, p < 0.05, respectively r = 0.265, p < 0.05 after
two weeks of H1-anti histamine treatment) at both times
of the assessment.
Conclusion
HCV infection reduces the anti-inflammatory effect of
H1-antihistamines in urticaria patients.
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